Please login to the form below

Not currently logged in
Email:
Password:

CROS NT appoints Andrew MacGarvey to lead new UK office

Contract research organisation's new facility will be based in Milton Keynes

CROS NT Andrew MacGarveyItalian contract research organisation CROS NT has expanded into the UK and appointed Andrew MacGarvey to lead operations from its new facility in Milton Keynes.

MacGarvey has over 15 years' experience within the pharmaceutical sector and as CROS NT's new vice president of UK and USA operations he will be tasked with growing ties with the contract research organisation's UK-based customers.

MacGarvey previously held senior management and director roles at multiple contract research organisation (CROs) in Europe and the US.

"I have followed the activities of CROS NT for some time," MacGarvey said. "I am excited by the opportunity to help with the growth of the business. CROS NT are focused on customer care, something that is very important to me. I will be bringing their great service to the UK and ultimately the US."

Verona-headquartered CROS NT's new UK base joins its existing facilities in Italy and Augsburg, Germany.

17th August 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....